MGMT Status as a Clinical Biomarker in Glioblastoma

摘要

Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have a sustained response to treatment. WhileO6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients remains debatable. Discrepancies betweenMGMTpromoter methylation status and treatment response in some patients may stem from inconsistencies betweenMGMTmethylation and expression levels in glioblastoma. Here, we discussMGMTas a biomarker and elucidate the discordance betweenMGMTmethylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice.